Targeting Nociceptors in Hidradenitis Suppurativa
NCT05403710
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hidradenitis Suppurativa
- Hyperhidrosis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Massachusetts, Worcester
- Last updated on ClinicalTrials.gov
- September 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- University of Massachusetts Chan Medical School · Worcester, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.